Jagged1 DNA Copy Number Variation Is Associated with Poor Outcome in Liver Cancer

American Journal of Pathology

Volumn 186, Issue 8, 2016, Pages 2055-2067

  Kawaguchi, Kazunori ^a   Honda, Masao ^a   Yamashita, Taro ^a   Okada, Hikari ^a   Shirasaki, Takayoshi ^a   Nishikawa, Masashi ^a   Nio, Kouki ^a   Arai, Kuniaki ^a   Sakai, Yoshio ^a   Yamashita, Tatsuya ^a   Mizukoshi, Eishiro ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; EPITHELIAL CELL ADHESION MOLECULE; JAGGED1; MESSENGER RNA; NOTCH RECEPTOR; SHORT HAIRPIN RNA; JAG1 PROTEIN, HUMAN; PROTEIN JAGGED 1;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CELL VIABILITY; CHROMOSOME 20P; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STEM CELL; TUMOR VOLUME; VERY ELDERLY; ANIMAL; DNA MICROARRAY; GENETICS; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TUMOR; MIDDLE AGED; MORTALITY; NONOBESE DIABETIC MOUSE; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, HEPATOCELLULAR; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; JAGGED-1 PROTEIN; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84990062574     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2016.04.011     Document Type: Article

References (43)

1. 1 Yang, J.D., Roberts, L.R., Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7 (2010), 448–458.
2. 2 Iida, H., Honda, M., Kawai, H.F., Yamashita, T., Shirota, Y., Wang, B.C., Miao, H., Kaneko, S., Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma. Gut 54 (2005), 843–851.
3. 3 Yamashita, T., Ji, J., Budhu, A., Forgues, M., Yang, W., Wang, H.Y., Jia, H., Ye, Q., Qin, L.X., Wauthier, E., Reid, L.M., Minato, H., Honda, M., Kaneko, S., Tang, Z.Y., Wang, X.W., EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136 (2009), 1012–1024.
4. 4 Yamashita, T., Honda, M., Nio, K., Nakamoto, Y., Takamura, H., Tani, T., Zen, Y., Kaneko, S., Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Cancer Res 70 (2010), 4687–4697.
5. 5 Kawai, H.F., Kaneko, S., Honda, M., Shirota, Y., Kobayashi, K., Alpha-fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis. Hepatology 33 (2001), 676–691.
6. 6 Pollack, J.R., Perou, C.M., Alizadeh, A.A., Eisen, M.B., Pergamenschikov, A., Williams, C.F., Jeffrey, S.S., Botstein, D., Brown, P.O., Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23 (1999), 41–46.
7. 7 Pollack, J.R., Sorlie, T., Perou, C.M., Rees, C.A., Jeffrey, S.S., Lonning, P.E., Tibshirani, R., Botstein, D., Borresen-Dale, A.L., Brown, P.O., Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 99 (2002), 12963–12968.
8. 8 Kawaguchi, K., Honda, M., Yamashita, T., Shirota, Y., Kaneko, S., Differential gene alteration among hepatoma cell lines demonstrated by cDNA microarray-based comparative genomic hybridization. Biochem Biophys Res Commun 329 (2005), 370–380.
9. 9 Pfeifer, A.M., Cole, K.E., Smoot, D.T., Weston, A., Groopman, J.D., Shields, P.G., Vignaud, J.M., Juillerat, M., Lipsky, M.M., Trump, B.F., Lechner, J.F., Harris, C.C., Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci U S A 90 (1993), 5123–5127.
10. 10 Espinoza, I., Miele, L., Notch inhibitors for cancer treatment. Pharmacol Ther 139 (2013), 95–110.
11. 11 Takebe, N., Nguyen, D., Yang, S.X., Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 141 (2014), 140–149.
12. 12 Li, Y.M., Xu, M., Lai, M.T., Huang, Q., Castro, J.L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J.G., Register, R.B., Sardana, M.K., Shearman, M.S., Smith, A.L., Shi, X.P., Yin, K.C., Shafer, J.A., Gardell, S.J., Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405 (2000), 689–694.
13. 13 Kornilova, A.Y., Das, C., Wolfe, M.S., Differential effects of inhibitors on the gamma-secretase complex. Mechanistic implications. J Biol Chem 278 (2003), 16470–16473.
14. 14 Hodgson, G., Hager, J.H., Volik, S., Hariono, S., Wernick, M., Moore, D., Nowak, N., Albertson, D.G., Pinkel, D., Collins, C., Hanahan, D., Gray, J.W., Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet 29 (2001), 459–464.
15. 15 Tang, Y.C., Amon, A., Gene copy-number alterations: a cost-benefit analysis. Cell 152 (2013), 394–405.
16. 16 Huang, X., Gollin, S.M., Raja, S., Godfrey, T.E., High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A 99 (2002), 11369–11374.
17. 17 Hyman, E., Kauraniemi, P., Hautaniemi, S., Wolf, M., Mousses, S., Rozenblum, E., Ringnér, M., Sauter, G., Monni, O., Elkahloun, A., Kallioniemi, O.P., Kallioniemi, A., Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 62 (2002), 6240–6245.
18. 18 Kusano, N., Shiraishi, K., Kubo, K., Oga, A., Okita, K., Sasaki, K., Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology 29 (1999), 1858–1862.
19. 19 Midorikawa, Y., Tsutsumi, S., Nishimura, K., Kamimura, N., Kano, M., Sakamoto, H., Makuuchi, M., Aburatani, H., Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma. Cancer Res 64 (2004), 7263–7270.
20. 20 Andersson, E.R., Sandberg, R., Lendahl, U., Notch signaling: simplicity in design, versatility in function. Development 138 (2011), 3593–3612.
21. 21 Vooijs, M., Liu, Z., Kopan, R., Notch: architect, landscaper, and guardian of the intestine. Gastroenterology 141 (2011), 448–459.
22. 22 Turnpenny, P.D., Ellard, S., Alagille syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 20 (2012), 251–257.
23. 23 Sekiya, S., Suzuki, A., Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest 122 (2012), 3914–3918.
24. 24 Benedito, R., Roca, C., Sörensen, I., Adams, S., Gossler, A., Fruttiger, M., Adams, R.H., The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137 (2009), 1124–1135.
25. 25 Doody, R.S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R.G., Aisen, P.S. Alzheimer's Disease Cooperative Study Steering Committee, Siemers, E., Sethuraman, G., Mohs, R., Semagacestat Study Group. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 369 (2013), 341–350.
26. 26 He, G., Luo, W., Li, P., Remmers, C., Netzer, W.J., Hendrick, J., Bettayeb, K., Flajolet, M., Gorelick, F., Wennogle, L.P., Greengard, P., Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467 (2010), 95–98.
27. 27 Maraver, A., Fernandez-Marcos, P.J., Herranz, D., Cañamero, M., Muñoz-Martin, M., Gómez-López, G., Mulero, F., Megías, D., Sanchez-Carbayo, M., Shen, J., Sanchez-Cespedes, M., Palomero, T., Ferrando, A., Serrano, M., Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 22 (2012), 222–234.
28. 28 Lobry, C., Ntziachristos, P., Ndiaye-Lobry, D., Oh, P., Cimmino, L., Zhu, N., Araldi, E., Hu, W., Freund, J., Abdel-Wahab, O., Ibrahim, S., Skokos, D., Armstrong, S.A., Levine, R.L., Park, C.Y., Aifantis, I., Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med 210 (2013), 301–319.
29. 29 Kannan, S., Sutphin, R.M., Hall, M.G., Golfman, L.S., Fang, W., Nolo, R.M., Akers, L.J., Hammitt, R.A., McMurray, J.S., Kornblau, S.M., Melnick, A.M., Figueroa, M.E., Zweidler-McKay, P.A., Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med 210 (2013), 321–337.
30. 30 López-Guerra, M., Xargay-Torrent, S., Rosich, L., Montraveta, A., Roldán, J., Matas-Céspedes, A., Villamor, N., Aymerich, M., López-Otín, C., Pérez-Galán, P., Roué, G., Campo, E., Colomer, D., The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia 29 (2015), 96–106.
31. 31 Thorgeirsson, S.S., Lee, J.S., Grisham, J.W., Functional genomics of hepatocellular carcinoma. Hepatology 43 (2006), S145–S150.
32. 32 Lee, J.S., Heo, J., Libbrecht, L., Chu, I.S., Kaposi-Novak, P., Calvisi, D.F., Mikaelyan, A., Roberts, L.R., Demetris, A.J., Sun, Z., Nevens, F., Roskams, T., Thorgeirsson, S.S., A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12 (2006), 410–416.
33. 33 Wang, F., Xia, X., Wang, J., Sun, Q., Luo, J., Cheng, B., Notch1 signaling contributes to the oncogenic effect of HBx on human hepatic cells. Biotechnol Lett 35 (2013), 29–37.
34. 34 Tschaharganeh, D.F., Chen, X., Latzko, P., Malz, M., Gaida, M.M., Felix, K., Ladu, S., Singer, S., Pinna, F., Gretz, N., Sticht, C., Tomasi, M.L., Delogu, S., Evert, M., Fan, B., Ribback, S., Jiang, L., Brozzetti, S., Bergmann, F., Dombrowski, F., Schirmacher, P., Calvisi, D.F., Breuhahn, K., Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 144 (2013), 1530–1542.e12.
35. 35 Scaltriti, M., Eichhorn, P.J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y.H., Guzmán, M., Gili, M., Rodríguez, O., Rodríguez, S., Pérez, J., Green, S.R., Mai, S., Rosen, N., Hudis, C., Baselga, J., Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 108 (2011), 3761–3766.
36. 36 Wei, W., Mok, S.C., Oliva, E., Kim, S.H., Mohapatra, G., Birrer, M.J., FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest 123 (2013), 4435–4448.
37. 37 Ahn, S.M., Jang, S.J., Shim, J.H., Kim, D., Hong, S.M., Sung, C.O., Baek, D., Haq, F., Ansari, A.A., Lee, S.Y., Chun, S.M., Choi, S., Choi, H.J., Kim, J., Kim, S., Hwang, S., Lee, Y.J., Lee, J.E., Jung, W.R., Jang, H.Y., Yang, E., Sung, W.K., Lee, N.P., Mao, M., Lee, C., Zucman-Rossi, J., Yu, E., Lee, H.C., Kong, G., A genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60 (2014), 1972–1982.
38. 38 Wang, K., Lim, H.Y., Shi, S., Lee, J., Deng, S., Xie, T., Zhu, Z., Wang, Y., Pocalyko, D., Yang, W.J., Rejto, P.A., Mao, M., Park, C.K., Xu, J., Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology 58 (2013), 706–717.
39. 39 Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., Kabbinavar, F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004), 2335–2342.
40. 40 Hottinger, A.F., Aissa, A.B., Espeli, V., Squiban, D., Dunkel, N., Vargas, M.I., Hundsberger, T., Mach, N., Schaller, K., Weber, D.C., Bodmer, A., Dietrich, P.Y., Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 110 (2014), 2655–2661.
41. 41 Bachelot, T., Garcia-Saenz, J.A., Verma, S., Gutierrez, M., Pivot, X., Kozloff, M.F., Prady, C., Huang, X., Khosravan, R., Wang, Z., Cesari, R., Tassell, V., Kern, K.A., Blay, J.Y., Lluch, A., Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer, 14, 2014, 166.
42. 42 Yamashita, T., Forgues, M., Wang, W., Kim, J.W., Ye, Q., Jia, H., Budhu, A., Zanetti, K.A., Chen, Y., Qin, L.X., Tang, Z.Y., Wang, X.W., EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68 (2008), 1451–1461.
43. 43 Noel, P.R., Barnett, K.C., Davies, R.E., Jolly, D.W., Leahy, J.S., Mawdesley-Thomas, L.E., Shillam, K.W., Squires, P.F., Street, A.E., Tucker, W.C., Worden, A.N., The toxicity of dimethyl sulphoxide (DMSO) for the dog, pig, rat and rabbit. Toxicology 3 (1975), 143–169.